Amgen Submits Application for Asthma Biologic
The agency also granted tezepelumab priority review with a PDUFA date sometime in the first quarter of 2022.
The FDA has accepted Amgen’s Biologics License Application (BLA) and granted priority review for tezepelumab to treat patients with severe, uncontrolled asthma. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.
The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is during the first quarter of 2022.
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in asthma.
The BLA was based on results from the PATHFINDER clinical trial program, including results from the pivotal NAVIGATOR phase 3 trial. Investigators in the NAVIGATOR study found that patients with severe, uncontrolled asthma who received tezepelumab had fewer exacerbations and better lung function, asthma control, and health-related quality of life than those who received placebo. Results were published May 13, 2021 in the New England Journal of Medicine.
The most frequently reported adverse events with tezepelumab were nasopharyngitis, upper respiratory tract infection and headache.
The FDA had granted Breakthrough Therapy Designation to Tezepelumab in September 2018.
“Severe asthma is a challenging, complex disease for physicians and millions of patients and has a high unmet medical need,” David M. Reese, M.D., executive vice president of research and development at Amgen said in a statement.
About 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children, according to Asthma and Allergy Foundation of America
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Understanding the Impact of Disease Severity on Quality of Life Patients with ILD in India
June 16th 2025More cases of interstitial lung disease (ILD) in India can be traced back to occupational exposure and other environmental causes compared with ILD in the U.S. A different set of exposures may affect the symptoms and course of the disease.
Read More
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
